Ginkgo Bioworks Holdings (DNA) Non-Current Assets (2020 - 2026)
Ginkgo Bioworks Holdings posted quarterly Non-Current Assets of $623.1 million for Q1 2026, down 14.52% year-on-year from $728.9 million in Q1 2025, and down 3.82% on a QoQ basis from $647.9 million in Q4 2025.
Ginkgo Bioworks Holdings (DNA) has 7 years of Non-Current Assets data on file, last reported at $623.1 million in Q1 2026.
- For the quarter ending Q1 2026, Non-Current Assets fell 14.52% year-over-year to $623.1 million; the trailing twelve-month figure through Mar 2026 stood at $2.7 billion (down 15.86% YoY), and the FY2025 full-year result was $647.9 million, down 16.37% from the prior year.
- Non-Current Assets for Q1 2026 stood at $623.1 million, down from $647.9 million in the prior quarter.
- Across five years, Non-Current Assets topped out at $1.1 billion in Q1 2023 and bottomed at $351.9 million in Q1 2022.
- The 5-year median for Non-Current Assets is $708.0 million (2025), against an average of $732.7 million.
- Peak annual rise in Non-Current Assets reached 213.05% in 2022, while the deepest fall reached 79.6% in 2022.
- A 5-year view of Non-Current Assets shows it stood at $1.1 billion in 2022, then tumbled by 39.08% to $663.6 million in 2023, then increased by 16.74% to $774.7 million in 2024, then dropped by 16.37% to $647.9 million in 2025, then dropped by 3.82% to $623.1 million in 2026.
- The last three Non-Current Assets figures came in at $623.1 million (Q1 2026), $647.9 million (Q4 2025), and $683.1 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | 4.56 Mn |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | 62,953.78 |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 486.60 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | 5.83 Mn |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | 30.30 Mn |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 14.75 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 22.66 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 910.24 Mn |
| 10 | Ginkgo Bioworks Holdings | 542.03 Mn | 542.03 Mn | 16.38 Mn | 623.12 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 623.12 Mn |
| Dec 31, 2025 | 647.86 Mn |
| Sep 30, 2025 | 683.08 Mn |
| Jun 30, 2025 | 707.98 Mn |
| Mar 31, 2025 | 728.93 Mn |
| Dec 31, 2024 | 774.71 Mn |
| Sep 30, 2024 | 818.40 Mn |
| Jun 30, 2024 | 841.89 Mn |
| Mar 31, 2024 | 678.74 Mn |
| Dec 31, 2023 | 663.59 Mn |
| Sep 30, 2023 | 884.55 Mn |
| Jun 30, 2023 | 1.07 Bn |
| Mar 31, 2023 | 1.09 Bn |
| Dec 31, 2022 | 1.09 Bn |
| Sep 30, 2022 | 408.69 Mn |
| Jun 30, 2022 | 395.37 Mn |
| Mar 31, 2022 | 351.89 Mn |
| Dec 31, 2021 | 347.95 Mn |
| Sep 30, 2021 | 340.02 Mn |
| Jun 30, 2021 | 1.73 Bn |
| Mar 31, 2021 | 1.73 Bn |
| Dec 31, 2020 | 248.61 Mn |